Overview

Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer

Status:
Completed
Trial end date:
2003-01-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to determine the activity of the weekly combination of docetaxel (Taxotere) and irinotecan in terms of response rate in subjects with advanced, previously untreated, non-small cell lung cancer. It is also to determine the activity of this combination in terms of response duration, time to progression, median survival, overall survival, and percent one-year survival, as well as the side-effect and toxicity profile of weekly Taxotere and weekly irinotecan.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi
Treatments:
Camptothecin
Docetaxel
Irinotecan